ReVision CEO John Kilcoyne Says the Company is Ready to Build a New Medtech Market in Ophthalmology

ReVision Optics built it – a corneal inlay capable of correcting presbyopia. The FDA approved it sooner than expected. Now the company needs to build it into a successful private-pay business.